Corcept Therapeutics (CORT, Financial), a pharmaceutical company specializing in hormone regulation therapies, experienced a significant stock movement with a 5.04% drop in its stock price. The share price reached $46.50, with a trading volume of 512,234 shares and a turnover rate of 0.49%, alongside a price volatility of 3.74%.
In its recent financial report, Corcept Therapeutics reported a revenue of $164 million, a net profit of $35.12 million, and earnings per share of $0.34. The company's gross profit stood at $161 million, with a price-to-earnings ratio of 37.50. Currently, no institutional ratings are available for buying, holding, or selling the stock.
Within the biotechnology sector, which saw an overall increase of 0.74%, several related stocks experienced notable gains. Companies such as Revolution Medicines Inc, Athira Pharma, Inc., and Eupraxia Pharmaceuticals Inc. saw substantial increases, while others like Theriva Biologics, Inc., Ensysce Biosciences, Inc., and Gri Bio, Inc. showed high turnover rates. Stocks with significant price amplitude included Klotho Neurosciences Inc, Tc Biopharm (Holdings) Plc, and Immatics N V.
